<DOC>
	<DOCNO>NCT02231671</DOCNO>
	<brief_summary>The purpose study see ALS-008176 take , broken , remove body .</brief_summary>
	<brief_title>A Phase 1 , Open-Label Study Absorption , Metabolism , Excretion Absolute Bioavailability ALS-008176</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Body mass index 18.0 32.0 kg/m2 ( inclusive ) total body weight &gt; 50 kg Creatinine clearance calculate Cockroft‚ÄêGault formula le 60 mL/min Clinically significant abnormal biochemistry , haematology urinalysis judge investigator sponsor medical monitor . Reticulocyte count , haemoglobin platelet count must less low limit normal subject . History clinically significant cardiovascular , renal , hepatic , chronic respiratory , GI , haematological , neurological , endocrinological , immunological , musculoskeletal disease uncontrolled medical illness ( eg active infection ) psychiatric disorder , judge investigator medical monitor . Clinically significant abnormal electrocardiogram ( ECG ) finding</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>